Stem Cells News and Research

RSS

Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

GenomePooling™ method is sensitive and accurate

Population Genetics Technologies Ltd., creator of innovative methods for genetic analyses and biomarker discovery, has successfully completed a pilot study to prove that its GenomePooling™ method is sensitive and accurate enough to detect even small percentages of gene variants within cancer tissue.

31 Jul 2012

Stem cell therapy holds promise for craniofacial bone repair

In the first human study of its kind, researchers found that using stem cells to re-grow craniofacial tissues-mainly bone-proved quicker, more effective and less invasive than traditional bone regeneration treatments.

31 Jul 2012

Parkinson’s disease treatment: an interview with Ted Dawson

Parkinson’s disease is a disorder which usually affects people in their 60’s and older. It is caused by the loss of dopamine neurons in the brain leading to rigidity, slowness of movement, tremor, problems with balance and so forth.

31 Jul 2012

Stem cells can actually replace dead tissue after heart attack very early in life

Stem cells can actually replace dead heart tissue after a heart attack very early in life — but those same cells lose that regenerative ability in adults, according to researchers at Cornell University and the University of Bonn.

31 Jul 2012

New drug shows promise for Long QT syndrome

Long QT syndrome, which results from genetic mutation or certain medications, can cause the heart to beat chaotically and the affected person to die suddenly. The chaotic heartbeat is due to abnormal electrical activity in the heart. In an electrocardiogram test, this abnormality appears as a wider-than-normal QT interval, a pattern of "hills" in a map of peaks and valleys corresponding to the heart contracting and relaxing.

30 Jul 2012

Burn wound MSCs potential source for skin grafting

Study findings suggest that burn wound eschar-derived mesenchymal cells represent a population of multipotent stem cells, which could be a new resource for engineering approaches to heal burn wounds.

30 Jul 2012

Osiris second quarter biosurgery product revenue increases 43% from previous quarter

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today its results for the second quarter ended June 30, 2012.

30 Jul 2012

Tenth patient treated in ACT's hESC derived RPE cell trial for SMD

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, today announced treatment of the final patient in the first patient cohort in its Phase 1/2 clinical trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).

30 Jul 2012

UTMB researchers receives NIH grant to develop engineered lung tissue for biomedical studies

University of Texas Medical Branch at Galveston researchers have been awarded a two-year, $1.25 million National Institutes of Health grant to develop a method of custom-growing human lung tissue to make a three-dimensional model for biomedical studies.

30 Jul 2012

Cedars-Sinai to develop stem cell treatments for patients with ALS

Cedars-Sinai Regenerative Medicine Institute today was awarded a $17.8 million grant from the California Institute for Regenerative Medicine to develop stem cell treatments for patients with ALS, also known as Lou Gehrig's Disease, a progressive, fatal and currently incurable neurodegenerative disease.

30 Jul 2012

ACT receives Australian patent for human retinal pigment epithelial cells

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it has been issued a patent in Australia, patent number 2005325753, "Improved modalities for the treatment of degenerative diseases of the retina."

28 Jul 2012

Roundup: Mass. lawmakers struggle to reach agreement on cost controls; $100M grant for Calif. stem cell research; N.C. to move mentally ill from elderly homes

The House and Senate are under the gun to reach an agreement on how to lower health care costs while improving care. A conference committee aims to have a bill out on Sunday. Their deadline is Monday evening. In the meantime, several major issues are still unresolved, including what to do about hospitals that use their market clout to demand high prices that are not based on higher quality. Attorney General Martha Coakley, the state's top insurers and several consumer groups argue that price is a critical issue.

28 Jul 2012

Bone marrow transplant eradicates traces of HIV in men

Two men with longstanding HIV infections no longer have detectable HIV in their blood cells following bone marrow transplants. The virus was easily detected in blood lymphocytes of both men prior to their transplants but became undetectable by eight months post-transplant. The men, who were treated at Brigham and Women's Hospital (BWH), have remained on anti-retroviral therapy.

27 Jul 2012

Fusion of FGFR and TACC gene leads to glioblastoma

Researchers at Columbia University Medical Center (CUMC) have discovered that some cases of glioblastoma, the most common and aggressive form of primary brain cancer, are caused by the fusion of two adjacent genes.

26 Jul 2012

Researchers decipher function of β-catenin in generating blood tissue stem cells

Researchers from IMIM (Hospital del Mar Medical Research Institute) have deciphered the function executed by a protein called β-catenin in generating blood tissue stem cells.

26 Jul 2012

Child who received first stem cell trachea transplant functioning well two years on

The first child stem cell-supported trachea transplant is functioning well two years on, according to an Article published Online First in The Lancet today. The follow-up of the procedure, carried out in 2010 at Great Ormond Street Hospital (GOSH), shows that the new organ has strengthened and does not appear to have induced any signs of rejection. The 13-year-old boy who received the transplant continues to breathe normally, has grown 11 cm in height and has returned to school. He does not require any anti-rejection therapy.

26 Jul 2012

AAQ chemical temporarily restores vision in blind mice

A team of University of California, Berkeley, scientists in collaboration with researchers at the University of Munich and University of Washington in Seattle has discovered a chemical that temporarily restores some vision to blind mice, and is working on an improved compound that may someday allow people with degenerative blindness to see again.

26 Jul 2012

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.

26 Jul 2012

New cell regeneration method uses gene therapy to repair bone tissue

Researchers at the Royal College of Surgeons in Ireland (RCSI) have developed a new method of repairing bone using synthetic bone graft substitute material, which combined with gene therapy, can mimic real bone tissue and has potential to regenerate bone in patients who have lost large areas of bone from either disease or trauma.

25 Jul 2012

NIH grants aim at creating 3-D tissue chips to help identify drug safety signals

Seventeen National Institutes of Health grants are aimed at creating 3-D chips with living cells and tissues that accurately model the structure and function of human organs such as the lung, liver and heart. Once developed, these tissue chips will be tested with compounds known to be safe or toxic in humans to help identify the most reliable drug safety signals - ultimately advancing research to help predict the safety of potential drugs in a faster, more cost-effective way.

25 Jul 2012